Biotech Values

[DewDiligence]

Daiichi Sankyo inks FoB collaboration with Coherus Biosciences (a new private company) for Enbrel and Rituxan knockoffs in certain Asian countries:

http://www.pharmatimes.com/Article/12-05-08/Coherus_launches_with_Daiichi_Sankyo_biosimilar_pact.aspx

[Coherus], which is headquartered in the San Francisco Bay Area and was founded in 2010, begins with a pipeline of five oncology and inflammatory disease therapeutics.

First to sign up is Daiichi Sankyo in a pact which will see the firms work together to advance biosimilar forms of the arthritis and psoriasis therapy Enbrel (etanercept) and the rheumatoid arthritis and cancer drug Rituxan (rituximab) developed by Coherus. Upon marketing approval, Daiichi Sankyo will commercialise these products in Japan, South Korea and Taiwan and specific financial terms of the agreement were not disclosed.